Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol
The experimentally established mechanism targets of Zacopride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.56 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.56 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.56 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.56 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.56 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.56 |
| ▸ | HTR3A | P46098 | 4/20 | 0.88 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.88 |
| ▸ | HTR3B | O95264 | 2/20 | 0.88 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.88 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.88 |
| ▸ | HTR5A | P47898 | 1/20 | 0.88 |
| ▸ | MEN1 | O00255 | 1/20 | 0.88 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.88 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.88 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.88 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.88 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.85 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zacopride SCHEMBL7288017 | 1.00 | HTR3A (0.88) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Zacopride SCHEMBL7288008 | 1.00 | HTR3A (0.88) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Zacopride SCHEMBL29567897 | 0.94 | HTR3A (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Zacopride SCHEMBL5373467 | 0.94 | HTR3A (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Zacopride SCHEMBL16003 | 0.94 | HTR3A (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| (R)Zacopride SCHEMBL5387843 | 0.94 | HTR3A (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Zacopride SCHEMBL7280994 | 0.93 | MAPK1 (0.98) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Zacopride SCHEMBL7280998 | 0.93 | MAPK1 (0.98) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Zacopride SCHEMBL667580 | 0.93 | MAPK1 (0.98) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Zacopride SCHEMBL7281576 | 0.93 | MAPK1 (0.98) | HTR3AHTR3EHTR3BHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030050226-A1 | Dopamine analog amide | SHASHOUA VICTOR E (US) | 2003-03-13 | — | — | US | disclosed |
| US-6407137-B2 | A PRODRUG COMPOUND CAPABLE OF FACILITATING THE PASSAGE OF A DRUG ACROSS THE BLOOD BRAIN BARRIER COMPRISING A FATTY ACID COUPLED TO A DRUG TO FORM A PRODRUG | PROTARGA, INC. | 2002-06-18 | — | — | US | disclosed |
| US-20010056116-A1 | Dopamine analog amide | LUITPOLD PHARMACEUTICALS, INC. | 2001-12-27 | — | — | US | disclosed |
| US-6258836-B1 | FATTY ACID COUPLED TO ANTIAIDS SUBSTANCE, ANTIBIOTIC, CHOLINERGIC AGONIST AND OTHER USES FOR PASSING THE BLOOD BRAIN BARRIER | PROTARGA, INC. | 2001-07-10 | — | — | US | disclosed |
| US-6107499-A | FACILITATING THE TRANSPORT OF A NEUROTRANSMITTER ACROSS THE BLOOD BRAIN BARRIER BY ADMINISTERING THE DRUG, A NEUROTRANSMITTER SUCH AS DOPAMINE COVALENTLY COUPLED TO A SINGLE, STRAIGHT-CHAINED FATTY ACID CARRIER MOLECULE | NEUROMEDICA, INC. (US) | 2000-08-22 | — | — | US | disclosed |
| US-6022880-A | Substituted pyridylamino indoles | HOECHST MARION ROUSSEL, INC. (US) | 2000-02-08 | — | — | US | disclosed |
| US-5994392-A | PASSAGE OF DRUG THROUGH BLOOD BRAIN BARRIER | NEUROMEDICA, INC. (US) | 1999-11-30 | — | — | US | disclosed |
| EP-0509402-B1 | Substituted 3-(Pyridinylamino)-indoles and benzo[b]thiophenes, a process for their preparation and their use as medicaments | HOECHST MARION ROUSSEL INC (US) | 1998-01-07 | — | — | EP | disclosed |
| US-5340936-A | Antipsychotic agents | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1994-08-23 | — | — | US | disclosed |
| US-5334599-A | Heteroaryl-8-azabicyclo[3,2,1]octanes as antipsychotic agents, 5-HT3 receptor antagonists and inhibitors of the reuptake of serotonin | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1994-08-02 | — | — | US | disclosed |
| US-5328920-A | Alleviating memory dysfunctions | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1994-07-12 | — | — | US | disclosed |
| US-5234931-A | Anxiolytic agents; antdepressants; schizophrenia; drug abuse; medical diagnosis | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1993-08-10 | — | — | US | disclosed |
| US-5177088-A | Cognition Activators | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1993-01-05 | — | — | US | disclosed |
| EP-0190915-B1 | Process for the preparation of 2-alkoxy-N-(1-azabicyclo[2.2.2]octan-3-yl) aminobenzamides | SYNTHELABO (FR) | 1992-10-28 | — | — | EP | disclosed |
| EP-0509402-A1 | Substituted 3-(Pyridinylamino)-indoles and benzo[b]thiophenes, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1992-10-21 | — | — | EP | disclosed |
| US-4870181-A | AMIDATION OF 3-AMINOQUINUCLIDINE SALT | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-09-26 | — | — | US | disclosed |
| EP-0190915-A2 | Process for the preparation of 2-alkoxy-N-(1-azabicyclo[2.2.2]octan-3-yl) aminobenzamides | SYNTHELABO (FR) | 1986-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056116-A1 | Dopamine analog amide | FABP7, SLC6A3, ALOX15 | ADRA2A 100/4885ADRA2B 305/4885ADRA2C 260/4885 |
| US-20030050226-A1 | Dopamine analog amide | FABP7, SLC6A3, ALOX15 | ADRA2A 100/4885ADRA2B 305/4885ADRA2C 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.